El Paso Health
HEALTH PLANS FOR EL PASOANS. BY EL PASOANS.

MEMORANDUM

TO: Valued CHIP, STAR & STAR+PLUS Providers

FROM: El Paso Health

DATE: 10/09/2024

RE: HHSC to Remove Oxbryta Products from all Formularies as of Oct. 10, 2024

On Sept. 25, 2024, Pfizer, the manufacturer of Oxbryta, announced a voluntary withdrawal of all Oxbryta (voxelotor) products from worldwide markets. On Sept. 26, 2024, the FDA followed with an announcement alerting patients and healthcare professionals about the voluntary withdrawal of Oxbryta due to safety concerns.

HHSC will remove the following Oxbryta products and their clinical prior authorization from all formularies as of Oct. 10, 2024.El Paso Health will also remove the following NDCs.

NDC	Drug Name
72786010101	OXBRYTA 500 MG TABLET
72786011102	OXBRYTA 300 MG TABLET FOR SUSP
72786011103	OXBRYTA 300 MG TABLET FOR SUSP
72786010202	OXBRYTA 300 MG TABLET
72786010203	OXBRYTA 300 MG TABLET

If you have any questions regarding this communication please contact our Provider Relations team at 915-532-3778 or email us at ProviderRelationsDG@elpasohealth.com.